FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2804010661> ?p ?o ?g. }

• W2804010661 endingPage "676" @default.
• W2804010661 startingPage "676" @default.
• W2804010661 abstract "Psoriasis of the scalp, palms and/or soles, and nails is challenging to treat.To evaluate the effect of guselkumab on psoriasis in specific body regions.VOYAGE 1 and VOYAGE 2 were, double-blind, placebo- and adalimumab-controlled studies of guselkumab conducted at 101 and 115 global sites, respectively, from November 3, 2014, to May 19, 2016. Patients had moderate to severe plaque psoriasis (Psoriasis Area and Severity Index score ≥12, Investigator's Global Assessment [IGA] score ≥3, and ≥10% body surface area with psoriasis). This post hoc data analysis was performed from February 10 through November 15, 2017.Patients were randomized to guselkumab, 100 mg (weeks 0 and 4, then every 8 weeks); placebo followed by guselkumab, 100 mg, starting at week 16; or adalimumab (80 mg [week 0] and 40 mg [week 1, then every 2 weeks]).Efficacy was assessed through week 24. End points included numbers of patients achieving scores of 0 or 1 (clear or near clear) or 0 (clear) on the scalp-specific IGA (ss-IGA), Physician's Global Assessment of the hands and/or feet (hf-PGA), and fingernail PGA (f-PGA) and percentage of improvement in target Nail Psoriasis Severity Index score.Of 1829 randomized patients (mean [SD] age, 43.6 [12.4] years; 1300 [71.1%] male, 1498 [81.9%] white), 1576 (86.2%) had psoriasis of the scalp; 501 (27.4%), palms and/or soles; and 1049 (57.4%), fingernails. At baseline, 1512 (82.7%), 461 (25.2%), and 928 (50.7%) patients had a score of 2 or higher on the ss-IGA, hf-PGA, and f-PGA, respectively, and were included in the analysis. Guselkumab was superior to placebo based on the proportion of patients achieving an ss-IGA score of 0 or 1 (560 [81.8%] vs 43 [12.4%]) at week 16 and to adalimumab (582 [85.0%] vs 329 [68.5%]) at week 24 (both P < .001); 479 (69.9%) in the guselkumab group vs 270 (56.3%) in the adalimumab group achieved an ss-IGA score of 0 (all P < .001). An hf-PGA score of 0 or 1 was achieved by 154 patients (75.5%) in the guselkumab group vs 15 (14.2%) in the placebo group at week 16 and 164 (80.4%) in the guselkumab group vs 91 (60.3%) in the adalimumab group at week 24; 153 (75.0%) in the guselkumab group vs 76 (50.3%) in the adalimumab group achieved an hf-PGA score of 0 (all P < .001). An f-PGA score of 0 or 1 was achieved by 196 patients (46.7%) in the guselkumab group vs 32 (15.2%) in the placebo group at week 16 (P < .001) and 252 (60.0%) in the guselkumab group vs 191 (64.3%) in the adalimumab group at week 24 (P = .11); 115 (27.4%) in the guselkumab group vs 83 (27.9%) in the adalimumab group achieved an f-PGA score of 0 (P = .63).Compared with adalimumab, guselkumab was associated with significant improvement in psoriasis on the scalp and palms and/or soles; magnitude of improvement in fingernails did not differ between treatments. These results may help dermatologists make treatment decisions for patients with psoriasis in difficult-to-treat body regions.ClinicalTrials.gov Identifiers: NCT02207231 and NCT02207244." @default.
• W2804010661 created "2018-06-01" @default.
• W2804010661 creator A5000398504 @default.
• W2804010661 creator A5014063407 @default.
• W2804010661 creator A5035197780 @default.
• W2804010661 creator A5037858775 @default.
• W2804010661 creator A5045822657 @default.
• W2804010661 creator A5053892310 @default.
• W2804010661 creator A5080237247 @default.
• W2804010661 creator A5081251444 @default.
• W2804010661 creator A5083633227 @default.
• W2804010661 date "2018-06-01" @default.
• W2804010661 modified "2023-10-18" @default.
• W2804010661 title "Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions" @default.
• W2804010661 cites W1590700846 @default.
• W2804010661 cites W1759089328 @default.
• W2804010661 cites W1931293371 @default.
• W2804010661 cites W1975941816 @default.
• W2804010661 cites W1982400355 @default.
• W2804010661 cites W1987452313 @default.
• W2804010661 cites W1987684216 @default.
• W2804010661 cites W1990128482 @default.
• W2804010661 cites W2031998019 @default.
• W2804010661 cites W2043309765 @default.
• W2804010661 cites W2049268603 @default.
• W2804010661 cites W2052408898 @default.
• W2804010661 cites W2096991001 @default.
• W2804010661 cites W2112172463 @default.
• W2804010661 cites W2116232969 @default.
• W2804010661 cites W2120422600 @default.
• W2804010661 cites W2142329760 @default.
• W2804010661 cites W2157870332 @default.
• W2804010661 cites W2168607358 @default.
• W2804010661 cites W2190836745 @default.
• W2804010661 cites W2410991937 @default.
• W2804010661 cites W2430969673 @default.
• W2804010661 cites W2529389767 @default.
• W2804010661 cites W2533556733 @default.
• W2804010661 cites W2546600532 @default.
• W2804010661 cites W2570140560 @default.
• W2804010661 cites W2570141807 @default.
• W2804010661 cites W4235991605 @default.
• W2804010661 cites W4236548038 @default.
• W2804010661 cites W4240768701 @default.
• W2804010661 cites W4243448275 @default.
• W2804010661 cites W4245137843 @default.
• W2804010661 cites W4249267846 @default.
• W2804010661 cites W4249991503 @default.
• W2804010661 cites W4290138250 @default.
• W2804010661 doi "https://doi.org/10.1001/jamadermatol.2018.0793" @default.
• W2804010661 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6145649" @default.
• W2804010661 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29799960" @default.
• W2804010661 hasPublicationYear "2018" @default.
• W2804010661 type Work @default.
• W2804010661 sameAs 2804010661 @default.
• W2804010661 citedByCount "81" @default.
• W2804010661 countsByYear W28040106612018 @default.
• W2804010661 countsByYear W28040106612019 @default.
• W2804010661 countsByYear W28040106612020 @default.
• W2804010661 countsByYear W28040106612021 @default.
• W2804010661 countsByYear W28040106612022 @default.
• W2804010661 countsByYear W28040106612023 @default.
• W2804010661 crossrefType "journal-article" @default.
• W2804010661 hasAuthorship W2804010661A5000398504 @default.
• W2804010661 hasAuthorship W2804010661A5014063407 @default.
• W2804010661 hasAuthorship W2804010661A5035197780 @default.
• W2804010661 hasAuthorship W2804010661A5037858775 @default.
• W2804010661 hasAuthorship W2804010661A5045822657 @default.
• W2804010661 hasAuthorship W2804010661A5053892310 @default.
• W2804010661 hasAuthorship W2804010661A5080237247 @default.
• W2804010661 hasAuthorship W2804010661A5081251444 @default.
• W2804010661 hasAuthorship W2804010661A5083633227 @default.
• W2804010661 hasBestOaLocation W28040106611 @default.
• W2804010661 hasConcept C126322002 @default.
• W2804010661 hasConcept C141071460 @default.
• W2804010661 hasConcept C142724271 @default.
• W2804010661 hasConcept C16005928 @default.
• W2804010661 hasConcept C168563851 @default.
• W2804010661 hasConcept C204787440 @default.
• W2804010661 hasConcept C27081682 @default.
• W2804010661 hasConcept C2777011040 @default.
• W2804010661 hasConcept C2777501473 @default.
• W2804010661 hasConcept C2778515351 @default.
• W2804010661 hasConcept C2779134260 @default.
• W2804010661 hasConcept C2780132546 @default.
• W2804010661 hasConcept C2780221984 @default.
• W2804010661 hasConcept C2780564577 @default.
• W2804010661 hasConcept C71924100 @default.
• W2804010661 hasConceptScore W2804010661C126322002 @default.
• W2804010661 hasConceptScore W2804010661C141071460 @default.
• W2804010661 hasConceptScore W2804010661C142724271 @default.
• W2804010661 hasConceptScore W2804010661C16005928 @default.
• W2804010661 hasConceptScore W2804010661C168563851 @default.
• W2804010661 hasConceptScore W2804010661C204787440 @default.
• W2804010661 hasConceptScore W2804010661C27081682 @default.
• W2804010661 hasConceptScore W2804010661C2777011040 @default.
• W2804010661 hasConceptScore W2804010661C2777501473 @default.
• W2804010661 hasConceptScore W2804010661C2778515351 @default.

• next